KaydedilenlerDerginizi ekleyin

Dergiler / BEYOGLU EYE JOURNAL / 2019 / Cilt: 4 - Sayı: 1

Refractive Results and Endothelial Cell Density After Eyecryl Phakic Intraocular Lens Implantation

Ufuk URDEM
Alper AĞCA
Sayfa
17–22
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: The results of Eyecryl phakic IOL implantation were favorable in terms of efficacy and safety.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study was an examination of the refractive results and complications encountered with implantation of the Eyecryl phakic intraocular lens (IOL) (Biotech Vision Care, Luzern, Switzerland).
📊
Temel Bulgular & Veri:Methods: IOL recipients with a follow-up period of at least 2 years were included the study.
💡
Sonuç & Katkı:Conclusion: The results of Eyecryl phakic IOL implantation were favorable in terms of efficacy and safety.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: This study was an examination of the refractive results and complications encountered with implantation of the Eyecryl phakic intraocular lens (IOL) (Biotech Vision Care, Luzern, Switzerland). Methods: IOL recipients with a follow-up period of at least 2 years were included the study. Uncorrected and corrected distance visual acuity (UDVA and CDVA, respectively), central endothelial cell density (ECD), and procedure-related complication data were recorded. Results: The study included 52 eyes from 26 patients. The efficacy index (postoperative UDVA/preoperative CDVA) was 1.32±1.09 in the first year and 1.39±1.03 in the second year. The safety index (postoperative CDVA/preoperative CDVA) was 1.69±1.16 at the last follow-up. None of the patients lost 2 or more lines of CDVA. The mean ECD loss was –4.51±9.69% at 1 year (p=0.005). There was no statistically significant ECD loss between the 1- and 2-year follow-up visits (p=0.794). Conclusion: The results of Eyecryl phakic IOL implantation were favorable in terms of efficacy and safety.

🔖

Bu Makaleye Atıf Yap

URDEM, U., AĞCA, A. (2019). Refractive Results and Endothelial Cell Density After Eyecryl Phakic Intraocular Lens Implantation. BEYOGLU EYE JOURNAL, Cilt: 4 - Sayı: 1, 17–22. https://ajindex.com/articles/143738

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Güell JL, Morral M, Kook D, Kohnen T. Phakic intraocular lenses part 1: historical overview, current models, selection criteria, and surgical techniques. J Cataract Refract Surg 2010;36:1976–93.
  2. Kohnen T, Kook D, Morral M, Güell JL. Phakic intraocular lenses: part 2: results and complications. J Cataract Refract Surg 2010;36:2168–94.
  3. Kohnen T, LaFontaine L, Andrew R; Study Investigators. Long-term safety follow-up of an anterior chamber angle-supported phakic intraocular lens. J Cataract Refract Surg 2017;43:1163– 1170. Stulting RD, John ME, Maloney RK, Assil KK, Arrowsmith PN, Thompson VM; U.S. Verisyse Study Group. Three-year results of Artisan/Verisyse phakic intraocular lens implantation. Results of the United States Food And Drug Administration clinical trial. Ophthalmology 2008;115:464–72.e1. Lee J, Kim Y, Park S, Bae J, Lee S, Park Y, et al. Long-term clinical results of posterior chamber phakic intraocular lens implanta-tion to correct myopia. Clin Exp Ophthalmol 2016;44:481–7.
  4. Kobashi H, Kamiya K, Igarashi A, Matsumura K, Komatsu M, Shimizu K. Long-term quality of life after posterior chamber phakic intraocular lens implantation and after wavefront-guided laser in situ keratomileusis for myopia. J Cataract Refract Surg 2014;40:2019–24.
  5. Dick HB, Budo C, Malecaze F, Güell JL, Marinho AA, Nuijts RM, et al. Foldable Artiflex phakic intraocular lens for the cor-rection of myopia: two-year follow-up results of a prospective European multicenter study. Ophthalmology 2009;116:671–7.
  6. Bohac M, Anticic M, Draca N, Kozomara B, Dekaris I, Gabric N, et al. Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery. Semin Ophthalmol 2017;32:725–733.
  7. Alfonso JF, Baamonde B, Fernández-Vega L, Fernandes P, González-Méijome JM, Montés-Micó R. Posterior chamber col-lagen copolymer phakic intraocular lenses to correct myopia: five-year follow-up. J Cataract Refract Surg 2011;37:873–80.
  8. Sanders DR, Doney K, Poco M; ICL in Treatment of Myopia Study Group. United States Food and Drug Administration clinical trial of the Implantable Collamer Lens (ICL) for mod-erate to high myopia: three-year follow-up. Ophthalmology 2004;111:1683–92.
  9. Ağca A, Çakır İ, Tülü Aygün B, Yaşa D, Yıldırım Y, Yıldız BK, et al. Visual and Refractive Outcomes of Small-Incision Len-ticule Extraction in High Myopia: 5-Year Results. J Ophthalmol 2018;2018:5893126. Yaşa D, Ağca A, Alkın Z, Çankaya Kİ, Karaküçük Y, Coşar MG, et al. Two-